<DOC>
	<DOCNO>NCT01162538</DOCNO>
	<brief_summary>Pilot open label multicentric study</brief_summary>
	<brief_title>To Evaluate Effectiveness Safety Containing Raltegravir Naive HIV NON B B Infected Patients</brief_title>
	<detailed_description>The population VIH1 B unimportant region Seine St Denis , tendency seem increase ( 47 % 2006 , 67 % 2007 ) . Most study evaluate clinical , immunologic virologic response ARV accord viral subcategories correspond show comparable result patient infected HIV 1 subcategory B non B . In spite reassuring result , necessary evaluate efficiency new ARV new class . It seem also necessary observe attentively profile resistance select carrier patient 's virus subcategories - B failure treatment . It allow determine , important polymorphism virus - B , evolution towards resistance make differently .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>In order eligible take part study , patient meet following criterion : Patient age least 18 year ; Treatment naive patient infect HIV1 ; Patients indicate treatment contain raltegravir Patient least 2 activates molecule combination therapy accord genotype realize visit selection . Patient history current evidence opportunist infection within 4 week selection Patient receive oral write ( information sheet ) information study agree computer processing his/her personal data . Patients chronic hepatitis , include chronic hepatitis B and/or C may enter study . Patients meet one follow criterion may take part study Patient reproductive potential without require use contraception Patient pregnant breastfeeding Patient use alcohol and\or drug and\or substance might interfere patient participation Patient infect HIV2 Patient severe hepatic insufficiency . ( liver enzymes &gt; 5N ) Patient follow laboratory value selection Platelets &lt; 40.000 cell / mm3 Haemoglobin &lt; 8 g / dl selection Neutrophils &lt; 500 / mm3 Patient associate treatment interaction Raltegravir ( Cf RCP Isentress Â® ) Patient consider investigator able conform imperative study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Raltegravir , non B subtype , naive patient</keyword>
</DOC>